Calcium Gluconate 10%
Brand names: Calcium Gluconate 10% Injection
Calcium gluconate 10% is an intravenous calcium salt used in emergencies for cardiac membrane protection in severe hyperkalaemia, symptomatic hypocalcaemia, and as an antidote in magnesium or calcium-channel-blocker toxicity and hydrofluoric acid burns.
Adult dose
Dose adjustments
No numeric adjustment stated in the UK SPC. Section 4.4: renal impairment may be associated with hypercalcaemia and secondary hyperparathyroidism, so in renal impairment parenteral calcium should be given only after careful assessment of the indication and the calcium-phosphate balance should be monitored; repeated or prolonged treatment is contraindicated in impaired renal function because of aluminium exposure. In severe renal insufficiency and renal failure, appropriate blood purification methods (haemodialysis or peritoneal dialysis) should be considered (text truncated in source).
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Hypercalcaemia (e.g. hyperparathyroidism, hypervitaminosis D, neoplastic disease with decalcification of bone, renal insufficiency, immobilisation osteoporosis, sarcoidosis, milk-alkali syndrome) and hypercalciuria
- Poisoning with cardiac glycosides, and patients receiving cardiac glycosides — the only exception may be where intravenous calcium is imperative for severe hypocalcaemic symptoms or acute severe hyperkalaemia placing the patient at immediate vital risk, if safer alternatives are unavailable and the oral route is not possible
- Co-administration with ceftriaxone in premature newborns up to a corrected age of 41 weeks and in full-term newborns up to 28 days of age (risk of ceftriaxone-calcium precipitation)
- Repeated or prolonged treatment in children under 18 years and in those with impaired renal function, due to the risk of aluminium exposure — the product is indicated for acute, symptomatic treatment only and must not be used to prepare total parenteral nutrition
Side effects
- Cardiac: bradycardia, cardiac arrhythmia, cardiac arrest, syncope (frequency not known)
- Vascular: hypotension, vasodilatation, circulatory collapse (possibly fatal), flushing (frequency not known)
- Administration-site: calcinosis cutis due to extravasation, possibly followed by skin ablation and necrosis, with cardiovascular and other systemic effects
- Nausea and vomiting; heat sensations and sweating
- Severe and in some cases fatal reactions following intravenous ceftriaxone plus calcium salt in preterm and full-term newborns aged <28 days (rare); aluminium accumulation and toxicity with repeated or prolonged treatment (microcytic anaemia, osteopenia, fractures, rickets, impaired bone mineralisation, neurotoxicity, hepatotoxicity)
Interactions
- Ceftriaxone — contraindicated in neonates as above; must not be mixed or co-administered (see sections 4.3 and 4.4)
- Cardiac glycosides (e.g. digoxin) — contraindicated in patients receiving them; if intravenous calcium is exceptionally necessary, adequate cardiac monitoring is mandatory and emergency treatment for serious arrhythmias must be available, as rapid calcium administration may precipitate myocardial digoxin toxicity
- Epinephrine (adrenaline) — calcium salts should be used with caution in patients receiving epinephrine (section 4.4)
- Sodium bicarbonate — must not be mixed with, or administered through the same intravenous line as, calcium gluconate due to the risk of precipitation; the same applies to phosphate-containing solutions
Clinical monograph
How it works
Calcium ions antagonise the membrane effects of hyperkalaemia by restoring the resting potential and stabilise myocardial and neuromuscular excitability.
Prescribing in practice
- It provides less elemental calcium per volume than calcium chloride, so the salts are not interchangeable and the correct salt and strength must be confirmed for the indication.
- It is less irritant than calcium chloride and so is often preferred for peripheral administration, but extravasation can still cause tissue injury and it should be given slowly with cardiac monitoring.
- Avoid co-administration with bicarbonate- or phosphate-containing fluids, which precipitate, and use caution in patients taking digoxin.
Monitoring
Monitor ECG continuously alongside serum calcium and potassium, and watch the cannula site during administration.
Counselling the patient
- Keep calcium-containing and bicarbonate/phosphate infusions in separate lines.
- In hyperkalaemia calcium only buys time; potassium-lowering measures must follow.
- Distinguish clearly between calcium gluconate and calcium chloride preparations.
Evidence & guidelines
Calcium gluconate for cardioprotection in hyperkalaemia is recommended in UK renal association and Resuscitation Council UK hyperkalaemia guidance.
Reference: UK Renal Association Hyperkalaemia Guidelines 2020; NICE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- AmlodipineRecommendedDihydropyridine Calcium Channel Blocker
- VerapamilRecommendedNon-Dihydropyridine Calcium Channel Blocker
- DiltiazemRecommendedNon-Dihydropyridine Calcium Channel Blocker
Featured in these MRCEM clinical pathways
Calcium Gluconate 10% is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.